VIP
- Category
- Brain & Cognition
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A naturally occurring peptide marketed for anti-inflammatory, lung, and gut effects. Human evidence is moderate for its anti-inflammatory and lung-relaxing effects, but the neuroprotective, sleep, and gut benefits rest on animal and mechanism data. It sharply lowers blood pressure, clears within minutes, and carries a theoretical tumor-promotion concern, with scant long-term safety data. Not FDA-approved; sold as an unregulated research-grade product.
Read Full recordStudied uses & evidence
Studied uses(6)
Potent anti-inflammatory and immunomodulatory effects
MediumReduced inflammatory markers in a small human trial; extensive supporting animal data.
Pulmonary vasodilation and treatment of pulmonary arterial hypertension
MediumInhaled VIP acutely lowers pulmonary vascular resistance in small human trials; long-term benefit unproven.
Neuroprotection against neurodegenerative disease
LowProtects neurons in animal models via a clear mechanism; no human trials conducted.
Evidence limits
- Evidence Level
- Moderate
VIP's clinical evidence base is paradoxically both extensive and incomplete. Preclinical evidence is among the strongest for any neuropeptide, with rigorous studies in Nature Medicine, JCI, Blood, and PNAS demonstrating potent immunomodulatory, neuroprotective, vasodilatory, and circadian regulatory effects. However, clinical translation has been limited. The pulmonary hypertension studies by Petkov et al. (2003) and Leuchte et al. (2008) showed clear benefits of inhaled VIP but remained small in scale. The COVID-19 ARDS trials yielded mixed results: Youssef et al. (2022, n=196) showed significant survival improvement, while the larger TESICO trial (2023; 471 randomized in the aviptadil comparison, 461 analyzed) was negative. The largest clinical experience comes from the Shoemaker CIRS protocol (10,000+ patients since 2008 using VIP nasal spray), which reports beneficial outcomes for biotoxin illness and chronic inflammation, but this evidence is observational and has not been validated through RCTs. Major gaps include the absence of large RCTs for autoimmune indications despite exceptional preclinical results, the absence of human neuroprotection trials and of randomized trials for the CIRS indication, and the short plasma half-life (~2 minutes IV), which presents formulation challenges for clinical development.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Severe hypotension
HighVIP is a potent vasodilator. Can cause dangerous blood pressure drops.
Diarrhea-predominant IBS
ModerateVIP increases intestinal secretion and motility, potentially worsening diarrhea.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Hypotension and cardiovascular effects
HighVery short plasma half-life (~2 minutes IV)
HighGastrointestinal side effects
ModerateLimited long-term safety data from controlled trials
HighPotential tumor-promoting effects in certain cancers
TheoreticalPregnancy and lactation safety unknown
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.